Suppr超能文献

由血清肌酐和胱抑素C计算得出的指标作为肝病中肝损伤、肌肉力量和肌肉减少症的预测指标。

Indices calculated by serum creatinine and cystatin C as predictors of liver damage, muscle strength and sarcopenia in liver disease.

作者信息

Ichikawa Tatsuki, Miyaaki Hisamitsu, Miuma Satoshi, Motoyoshi Yasuhide, Yamashima Mio, Yamamichi Shinobu, Koike Makiko, Takahashi Youichi, Honda Tetsurou, Yajima Hiroyuki, Uehara Ryouhei, Hino Naoyuki, Hirata Ryousuke, Taura Naota, Nakao Kazuhiko

机构信息

Department of Gastroenterology, Nagasaki Harbor Medical Center, Nagasaki 850-8555, Japan.

Innovation and Translational Research Center, Nagasaki Harbor Medical Center, Nagasaki 850-8555, Japan.

出版信息

Biomed Rep. 2020 Mar;12(3):89-98. doi: 10.3892/br.2020.1273. Epub 2020 Jan 24.

Abstract

Serum creatinine (Cr)-based glomerular filtration rate (CrGFR) is overestimated in liver disease. The present study evaluated whether the difference in CrGFR and cystatin C (CysC) GFR (dGFR) is significant in liver disease. The Cr-to-CysC ratio and sarcopenia index (SI) have been reported to correlate with muscle volume. An estimated total body muscle mass with Cr, CysC and calculated body muscle mass (CBMM) has also been reported to correlate with muscle mass. The applicability of dGFR, SI and CBMM for liver disease were evaluated. A total of 313 patients with liver damage were evaluated for Child-Pugh score, albumin-bilirubin (ALBI) score, model for end-stage liver disease, fibrosis-4, Cr, CysC, Cr-based estimated GFR (CreGFR), CysCGFR and grip strength. Of the 313 patients, 199 were evaluated using cross-sectional computed tomography (CT) of the third lumbar vertebra to determine the skeletal muscle (SM) mass. dGFR, CBMM and SI were compared to liver damage, muscle strength and muscle mass. In the 313 patients, dGFR was correlated with age, ALBI and grip strength; CBMM was correlated with body mass index (BMI) and grip strength; and SI was correlated with BMI and grip strength. In patients evaluated with CT, the correlation coefficients for CBMM and SI with SM were 0.804 and 0.293, respectively. Thus, CBMM and SI were associated with sarcopenia. The relationship between dGFR and ALBI does not differ with different grades of CrGFR-based chronic kidney disease (CKD). dGFR is a marker of liver damage and muscle strength regardless of CKD. CBMM and SI are markers for sarcopenia in liver disease.

摘要

基于血清肌酐(Cr)的肾小球滤过率(CrGFR)在肝脏疾病中被高估。本研究评估了在肝脏疾病中CrGFR与胱抑素C(CysC)肾小球滤过率(CysCGFR)的差异(dGFR)是否显著。据报道,Cr与CysC的比值以及肌肉减少症指数(SI)与肌肉体积相关。据报道,通过Cr、CysC估算的全身肌肉总量以及计算得出的身体肌肉量(CBMM)也与肌肉量相关。评估了dGFR、SI和CBMM在肝脏疾病中的适用性。总共对313例肝损伤患者进行了Child-Pugh评分、白蛋白-胆红素(ALBI)评分、终末期肝病模型、纤维化-4、Cr、CysC、基于Cr的估算肾小球滤过率(CreGFR)、CysCGFR和握力评估。在这313例患者中,199例接受了第三腰椎的横断面计算机断层扫描(CT)以确定骨骼肌(SM)量。将dGFR、CBMM和SI与肝损伤、肌肉力量和肌肉量进行比较。在这313例患者中,dGFR与年龄、ALBI和握力相关;CBMM与体重指数(BMI)和握力相关;SI与BMI和握力相关。在接受CT评估的患者中,CBMM和SI与SM的相关系数分别为0.804和0.293。因此,CBMM和SI与肌肉减少症相关。基于CrGFR的不同等级慢性肾脏病(CKD)中,dGFR与ALBI的关系并无差异。无论CKD情况如何,dGFR都是肝损伤和肌肉力量的标志物。CBMM和SI是肝脏疾病中肌肉减少症的标志物。

相似文献

4
6
Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with chronic obstructive pulmonary disease.
Clin Nutr. 2021 Mar;40(3):1274-1280. doi: 10.1016/j.clnu.2020.08.010. Epub 2020 Aug 19.
7
Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancer.
BMC Gastroenterol. 2022 Jan 19;22(1):26. doi: 10.1186/s12876-022-02093-4.
8
Association between oral frailty and cystatin C-related indices-A questionnaire (OFI-8) study in general internal medicine practice.
PLoS One. 2023 Apr 24;18(4):e0283803. doi: 10.1371/journal.pone.0283803. eCollection 2023.
9
Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours.
Front Nutr. 2022 Sep 2;9:963265. doi: 10.3389/fnut.2022.963265. eCollection 2022.
10
Impact of the serum creatinine and cystatin C ratio for prediction of sarcopenia and prognosis in biliary tract cancer.
Int J Clin Oncol. 2024 Jul;29(7):1002-1011. doi: 10.1007/s10147-024-02539-7. Epub 2024 Apr 29.

引用本文的文献

1
Comparison of sarcopenia screening indices using serum creatinine and cystatin C in metabolic dysfunction-associated steatotic liver disease.
Front Med (Lausanne). 2025 Aug 7;12:1633837. doi: 10.3389/fmed.2025.1633837. eCollection 2025.
2
The Predictive Power of the Cystatin C-Creatinine Score in Assessing Frailty.
J Cachexia Sarcopenia Muscle. 2025;16(4):e70040. doi: 10.1002/jcsm.70040.
3
What Does Sarcopenia Have to Do with Nonalcoholic Fatty Liver Disease?
Life (Basel). 2023 Dec 25;14(1):37. doi: 10.3390/life14010037.
4
PIVKA‑II is associated with liver function, bone metabolism, and muscle function in patients with liver disease.
Biomed Rep. 2023 Nov 13;20(1):2. doi: 10.3892/br.2023.1690. eCollection 2024 Jan.
5
Association between oral frailty and cystatin C-related indices-A questionnaire (OFI-8) study in general internal medicine practice.
PLoS One. 2023 Apr 24;18(4):e0283803. doi: 10.1371/journal.pone.0283803. eCollection 2023.
6
Serum creatinine/cystatin C ratio as a muscle mass evaluating tool and prognostic indicator for hospitalized patients: A meta-analysis.
Front Med (Lausanne). 2023 Jan 9;9:1058464. doi: 10.3389/fmed.2022.1058464. eCollection 2022.
7
Serum cystatin C is an early renal dysfunction biomarker in patients with hepatitis C virus.
Egypt Liver J. 2022;12(1):67. doi: 10.1186/s43066-022-00231-x. Epub 2022 Nov 24.
8
Sarcopenia in Chronic Liver Disease: A Metabolic Perspective.
J Clin Transl Hepatol. 2022 Dec 28;10(6):1213-1222. doi: 10.14218/JCTH.2022.00239. Epub 2022 Aug 9.
10
A Novel Application of Serum Creatinine and Cystatin C to Predict Sarcopenia in Advanced CKD.
Front Nutr. 2022 Feb 25;9:828880. doi: 10.3389/fnut.2022.828880. eCollection 2022.

本文引用的文献

1
Estimation of renal function in patients with liver cirrhosis: Impact of muscle mass and sex.
J Hepatol. 2019 May;70(5):847-854. doi: 10.1016/j.jhep.2018.12.030. Epub 2019 Jan 8.
2
Correlation and prognostic accuracy between noninvasive liver fibrosismarkers and portal pressure in cirrhosis: Role of ALBI score.
PLoS One. 2018 Dec 12;13(12):e0208903. doi: 10.1371/journal.pone.0208903. eCollection 2018.
4
Physical inactivity and protein energy wasting play independent roles in muscle weakness in maintenance haemodialysis patients.
PLoS One. 2018 Aug 1;13(8):e0200061. doi: 10.1371/journal.pone.0200061. eCollection 2018.
6
Validation of the sarcopenia index to assess muscle mass in the critically ill: A novel application of kidney function markers.
Clin Nutr. 2019 Jun;38(3):1362-1367. doi: 10.1016/j.clnu.2018.05.031. Epub 2018 Jun 8.
7
Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B.
Aliment Pharmacol Ther. 2018 Aug;48(3):300-312. doi: 10.1111/apt.14843. Epub 2018 Jun 19.
8
Decreased the creatinine to cystatin C ratio is a surrogate marker of sarcopenia in patients with type 2 diabetes.
Diabetes Res Clin Pract. 2018 May;139:52-58. doi: 10.1016/j.diabres.2018.02.025. Epub 2018 Feb 27.
9
Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis.
Dig Dis Sci. 2018 Mar;63(3):665-675. doi: 10.1007/s10620-017-4897-z. Epub 2018 Feb 1.
10
The sarcopenia index: A novel measure of muscle mass in lung transplant candidates.
Clin Transplant. 2018 Mar;32(3):e13182. doi: 10.1111/ctr.13182. Epub 2018 Jan 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验